Design2Optimize® is part of Lonza’s integrated AI-enabled toolkit, designed to support pharmaceutical innovators in overcoming early phase challenges. Whether you're dealing with complex synthesis routes, solubility issues, or tight timelines, Design2Optimize® helps you:
Reduce experimental burden
Minimize the number of lab experiments needed using model directed experimental design.
Improve process robustness
Refine your development path with predictive modeling that enhances reliability and scalability.
Enable “what-if” testing
Explore alternative pathways and conditions virtually - saving time and resources.
Support scale-up and commercialization
Ensure your process is ready for the next phase with confidence.
- Up to 25% shorter development timelines. Cost saving through material-, resource and time-sparing approaches
- Highly efficient route to improved process understanding
- A robust process, designed using science-based approaches and digital twin capabilities
- A mathematically optimized process
These measurable gains make Lonza Design2Optimize® one of Lonza’s most effective accelerated drug development services, offering speed without compromise on quality or scientific integrity.
Lonza Design2Optimize® works seamlessly with other AI-enabled tools such as:
AI-Enabled Route Scouting
Identify efficient synthetic pathways.
HTE (High-Throughput Experimentation)
Rapidly screen reaction conditions.
SFS (Solid Form Services)
Select the most stable and manufacturable form.
PBPK Modeling (Physiologically-Based Pharmacokinetic Modeling)
Predict absorption and guide formulation strategy.
Together, these tools create a powerful ecosystem that accelerates your molecule’s journey from preclinical to Phase I - and beyond.
In a recent case study, Lonza's AI-enabled toolkit helped a customer:
- Reduce synthesis steps from 7 to 5
- Eliminate chromatography
- Deliver 100g of material at >99% purity
- Save 11-14 weeks and avoid 700L of solvent
These results show how Lonza's AI Enabled Toolkit supports accelerated drug development in practice - bringing together predictive science, automation and deep process knowledge to achieve measurable improvements in efficiency and scalability.
Lonza CDMO small molecules – Design2Optimize® is an integrated development approach focused on designing robust, scalable, and cost-effective drug substance processes from the earliest stages. It combines route design, process optimization, and data driven development to support faster and more reliable scaleup.
Early design and optimization help reduce late-stage development risk, minimize rework, and improve commercial readiness. With Lonza CDMO small molecules – Design2Optimize®, companies can make informed decisions on synthetic routes, raw materials, and process parameters, early, improving long-term manufacturability and supply security.
Lonza CDMO small molecules – Design2Optimize® supports:
- Early development and preclinical stages
- IND-enabling and clinical development
- Preparation for late-phase and commercial manufacturing
This ensures a smooth transition from development to scalable GMP production.
Lonza’s Design2Optimize® capabilities include:
- Efficient development of process understanding
- Creation of a Digital Twin
- Robustness analysis
- Multicriterial optimisation
By applying strong process understanding, early risk identification, and data-driven optimization, Lonza CDMO small molecules – Design2Optimize® reduces the likelihood of issues during scale-up, tech transfer, or regulatory review. This proactive approach supports predictable timelines and reliable outcomes.
Yes. Lonza CDMO small molecules – Design2Optimize® is particularly valuable for complex chemistries, highly functionalized molecules, and challenging synthetic routes. Lonza’s scientific expertise helps overcome technical hurdles while maintaining quality and efficiency.
Lonza CDMO small molecules – Design2Optimize® is ideal for:
- Biotech companies advancing first-in-class or differentiated molecules
- Pharma companies optimizing early-stage pipelines
- Organizations seeking to de risk development before clinical or commercial investment